| Symbol | GLMD |
|---|---|
| Name | GALMED PHARMACEUTICALS LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | C/O MEITAR LAW OFFICES,ABBA HILLEL SILVER RD., RAMAT GAN, 5250608, Israel |
| Telephone | +972 36938448 |
| Fax | — |
| — | |
| Website | https://www.galmedpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001595353 |
| Description | Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Additional info from NASDAQ: |
Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinsons Disease, Targeting $6 Billion Market
Read moreGalmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinsons Disease, Targeting $6 Billion Market
Read moreGalmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Read moreGalmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
Read moreGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Read moreGalmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Read moreNew Form 424B3 - Galmed Pharmaceuticals Ltd. <b>Filed:</b> 2026-06-22 <b>AccNo:</b> 0001493152-26-029481 <b>Size:</b> 859 KB
Read moreGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Read moreGalmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
Read moreNew Form POS EX - Galmed Pharmaceuticals Ltd. <b>Filed:</b> 2026-06-08 <b>AccNo:</b> 0001493152-26-027646 <b>Size:</b> 44 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07251712 | Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meg… | Phase1 | Healthy | Recruiting | 2025-12-25 | 2026-05-15 | ClinicalTrials.gov |
| NCT06095986 | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine… | Phase2 | Primary Sclerosing Cholangitis | Withdrawn | 2025-06-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06502561 | Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets | Phase1 | Healthy | Completed | 2025-02-15 | 2025-11-17 | ClinicalTrials.gov |
| NCT05857215 | A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Su… | Phase1 | Inflammatory Disease | Completed | 2021-03-05 | 2021-07-01 | ClinicalTrials.gov |
| NCT05874336 | An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability a… | Phase1 | NASH | Completed | 2020-06-17 | 2020-08-11 | ClinicalTrials.gov |
| NCT03774173 | Comparison of Aramchol Concentrations With Once or Twice Daily Dosing | Phase1 | Healthy | Completed | 2018-12-08 | 2019-03-05 | ClinicalTrials.gov |
| NCT03760848 | Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Ara… | Phase1 | Healthy | Completed | 2018-11-12 | 2019-02-02 | ClinicalTrials.gov |
| NCT02803996 | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administer… | Phase1 | Healthy Volunteers | Completed | 2016-05-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02279524 | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Vers… | Phase2 | Fatty Liver | Completed | 2015-04-29 | 2018-05-22 | ClinicalTrials.gov |
| NCT02325492 | Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of … | Phase2 | Gallstones | Terminated | 2014-10-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02374437 | Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food E… | Phase1 | Healthy Volunteers | Completed | 2014-04-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01362361 | TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxalipla… | Phase2 | Colorectal Cancer | Completed | 2011-06-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01094158 | Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohe… | Phase2 | Non-Alcoholic Fatty Liver Disease | Completed | 2010-11-01 | 2012-01-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Aramchol free acid | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06502561 |
| Aramchol meglumine | Other | Phase PHASE1 | Healthy | COMPLETED | NCT06502561 |
| Aramchol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03774173 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Aramchol | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Placebo | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Aramchol | Other | Phase PHASE2 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT01094158 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02374437 |
| Aramchol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02374437 |
| Ultrasound | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Aramchol | Other | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Aramchol | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Atorvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Midazolam | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Aramchol | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| mFOLFOX6+placebo | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01362361 |
| mFOLFOX6 + BIBF 1120 | Other | Phase PHASE2 | Colorectal Cancer | COMPLETED | NCT01362361 |
| Aramchol | Other | Phase PHASE2 | Fatty Liver | COMPLETED | NCT02279524 |
| amilo-5MER | Other | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT05857215 |
| Aramchol | Other | Phase PHASE1 | NASH | COMPLETED | NCT05874336 |
| Aramchol meglumine | Other | Phase PHASE2 | Primary Sclerosing Cholangitis | WITHDRAWN | NCT06095986 |
| Aramchol free acid | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol meglumine | Other | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol | Other | Phase PHASE1 | Healthy | RECRUITING | NCT07251712 |
| Aramchol free acid | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| Aramchol meglumine | DRUG | Phase PHASE1 | Healthy | ACTIVE_NOT_RECRUITING | NCT06502561 |
| amilo-5MER | DRUG | Phase PHASE1 | Inflammatory Disease | COMPLETED | NCT05857215 |
| Atorvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Midazolam | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03760848 |
| Ultrasound | DEVICE | Phase PHASE2 | Gallstones | TERMINATED | NCT02325492 |
| Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT02803996 |
| Aramchol | DRUG | Phase PHASE1 | Healthy | RECRUITING | NCT07251712 |